CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
We have now added a new section called the "Assay History List" to the "At A Gla...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...